department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Exdensur · pharmadog

pharmadog
drugs
Exdensur

drug

patient view →

depemokimab

Marketedupdated 2mo ago

by $GSK GSK plc

Approved

community read0 votes

indications

investigational

Asthma

all catalysts(1)

approval · 1

News(0)

no news has mentioned this drug yet

brand

Exdensur

generic

depemokimab-ulaa

indication

Nasal Polyps (Nasal Polyposis)

phase

marketed

EXDENSUR (DEPEMOKIMAB-ULAA) — FDA approval

Data sources

openFDA · ClinicalTrials.gov

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

drugEXDENSUR4 co-mentions · 1 sources
tagApproval4 co-mentions · 1 sources
companyGlaxoSmithKline LLC2 co-mentions · 1 sources

Trials studying depemokimab

phase3Depemokimab Asthma Imaging and Bronchoscopy Sub-Studyrecruitingn=150
phase3Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)recruitingn=960
phase3A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthmanot yet recruitingn=456
phase3An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)completedn=641
phase3Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polypscompletedn=276
phase3Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trialrecruitingn=123
phase3eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammationrecruitingn=1,196
phase3Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)active not recruitingn=163

more trials →